In response to the ongoing paradigm shift in how neurodegenerative diseases are defined and diagnosed—as well as the new hope for a breakthrough in disease-modifying drugs— The Journal of Nuclear Medicine has issued a supplement on molecular imaging of neurodegeneration. The supplement provides an up-to-date overview on the different aspects of molecular imaging in neurodegeneration and a discussion on what the future will bring to the field.
Neurodegenerative disorders encompass most dementias, movement disorders, amyotrophic lateral sclerosis, Creutzfeldt–Jakob disease, and other diseases. Disease-specific trigger events in neurodegenerative disorders are still mainly unknown, and consequently, no preventive or curative treatment is currently available. As the incidence of most neurodegenerative disorders increases with age, they are of enormous socioeconomic relevance in our aging societies.
“In the clinic, molecular imaging has the potential to improve early and differential diagnosis and to stratify and monitor therapy in these disorders. Meanwhile, in research, these techniques improve our understanding of the underlying pathophysiology and pathobiochemistry of these disorders and allow for drug testing,” said supplement guest editors Henryk Barthel, MD, PhD, professor in the Klinik und Poliklinik für Nuklearmedizin at the University of Leipzig in Germany, and Victor L. Villemagne, MD, professor of psychiatry at the University of Pittsburgh in Pennsylvania. “There is great enthusiasm about advancing this facet of the field of molecular imaging, and the future is bright.”
Articles in the supplement include:
The JNM Molecular Imaging of Neurodegeneration Supplement is available at https://jnm.snmjournals.org/content/63/Supplement_1 .
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org .
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 14 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org .
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org .
Journal of Nuclear Medicine